This episode examines antihelminthic therapy as the pharmacology of selective vulnerability. Helminths are biologically sophisticated, multicellular organisms-far closer to us than bacteria-yet they harbour unique neuromuscular and metabolic features that drugs can exploit. We explore mechanisms that paralyse, starve, or dislodge worms, and why cure often depends as much on host immunity and environment as on the drug itself. Precision, safety, and public-health context are central themes.

Key takeaways to anchor learning:

* Size is not simplicity: why helminths demand targeted, gentle strategies.

* Neuromuscular targets: paralysis and expulsion as therapeutic goals.

* Metabolic vulnerabilities: energy pathways distinct enough to exploit.

* Safety first: pregnancy, neurocysticercosis, and inflammatory reactions.

* Population perspective: mass drug administration and reinfection dynamics.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe